3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Sarcoma
3
Carcinoma, Renal Cell
3
Leiomyosarcoma
2
Solid Neoplasm
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Refractory or Recurrent Solid Tumor
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Nerve Sheath Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Histiocytoma, Angiomatoid Fibrous
1
Granuloma, Plasma Cell
1
Glioblastoma
1
Fibrosarcoma
1
Dermatofibrosarcoma
1
Chondrosarcoma, Mesenchymal
1
Chondrosarcoma, Extraskeletal Myxoid
1
Carcinosarcoma
1
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Refractory or Recurrent Solid Tumor
×
pazopanib
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled